Septerna (NASDAQ:SEPN) Insider Sells $219,250.00 in Stock

Septerna, Inc. (NASDAQ:SEPN) insider Samira Shaikhly sold 6,250 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $35.08, for a total transaction of $219,250.00. Following the completion of the transaction, the insider directly owned 793 shares of the company’s stock, valued at $27,818.44. This trade represents a 88.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Samira Shaikhly also recently made the following trade(s):

• On Monday, June 1st, Samira Shaikhly sold 5,935 shares of Septerna stock. The stock was sold at an average price of $28.93, for a total transaction of $171,699.55.
• On Tuesday, May 26th, Samira Shaikhly sold 11,798 shares of Septerna stock. The stock was sold at an average price of $30.06, for a total transaction of $354,647.88.

Septerna Price Performance

NASDAQ SEPN traded down $0.86 on Tuesday, hitting $35.17. The stock had a trading volume of 284,028 shares, compared to its average volume of 299,736. The business’s fifty day moving average price is $27.39 and its 200 day moving average price is $26.88. The stock has a market cap of $1.59 billion, a price-to-earnings ratio of -43.42 and a beta of 2.39. Septerna, Inc. has a 52-week low of $9.85 and a 52-week high of $37.01.

Septerna (NASDAQ:SEPN) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.23. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. The business had revenue of $26.52 million for the quarter, compared to analyst estimates of $16.98 million. As a group, sell-side analysts anticipate that Septerna, Inc. will post -1.57 EPS for the current year.

Institutional Trading of Septerna

Several hedge funds have recently made changes to their positions in SEPN. Group One Trading LLC grew its stake in shares of Septerna by 111.8% in the 4th quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after buying an additional 8,955 shares during the period. Global Retirement Partners LLC purchased a new stake in shares of Septerna in the 4th quarter valued at approximately $35,000. Russell Investments Group Ltd. purchased a new stake in shares of Septerna in the 3rd quarter valued at approximately $36,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Septerna in the 4th quarter valued at approximately $53,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Septerna in the 4th quarter valued at approximately $61,000.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Truist Financial boosted their price objective on shares of Septerna from $34.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. Guggenheim started coverage on shares of Septerna in a research report on Thursday, June 11th. They set a “buy” rating and a $52.00 target price for the company. JPMorgan Chase & Co. boosted their target price on shares of Septerna from $34.00 to $38.00 and gave the company an “overweight” rating in a research report on Tuesday, March 24th. Zacks Research upgraded shares of Septerna from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $60.00 target price on shares of Septerna in a research report on Tuesday, March 10th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $45.78.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.